|
1
|
Cunningham D, Allum WH, et al: Magic Trial
Participants. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mathew ST, Devi SG, Prasanth VV and Vinod
B: Efficacy and safety of COX-2 inhibitors in the clinical
management of arthritis: Mini review. ISRN Pharmacol.
2011:4802912011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dannenberg AJ and Subbaramaiah K:
Targeting cyclooxygenase-2 in human neoplasia: rationale and
promise. Cancer Cell. 4:431–436. 2003. View Article : Google Scholar
|
|
5
|
Schönthal AH: Direct non-cyclooxygenase-2
targets of celecoxib and their potential relevance for cancer
therapy. Br J Cancer. 97:1465–1468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chuang HC, Kardosh A, Gaffney KJ, Petasis
NA and Schönthal AH: COX-2 inhibition is neither necessary nor
sufficient for celecoxib to suppress tumor cell proliferation and
focus formation in vitro. Mol Cancer. 7:382008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Agboola O: Adjuvant treatment in gastric
cancer. Cancer Treat Rev. 20:217–240. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cunningham D, Allum WH, et al:
Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshida K, Yamaguchi K, et al: Challenge
for a better combination with basic evidence. Int J Clin Oncol.
13:212–219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin Mao-Lin: New progress in advanced
gastric cancer systemic chemotherapy. Waike Lilun Yushijian.
8:18–20. 2003.(In Chinese).
|
|
13
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bertout JA, Patel SA and Simon MC: The
impact of O2 availability on human cancer. Nat Rev
Cancer. 8:967–975. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin CM, Ferdous A, Gallardo T, et al:
Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes
cytoprotection in cardiac side population cells. Circ Res.
102:998–1001. 2008. View Article : Google Scholar
|
|
18
|
Nichols J, Zevnik B, Anastassiadis K, et
al: Formation of pluripotent stem cells in the mammalian embryo
depends on the POU transcription factor Oct4. Cell. 95:379–391.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tai MH, Chang CC, Kiupel M, Webster JD,
Olson LK and Trosko JE: Oct4 expression in adult human stem cells:
evidence in support of the stem cell theory of carcinogenesis.
Carcinogenesis. 26:495–502. 2005. View Article : Google Scholar
|
|
20
|
Covello KL, Kehler J, Yu H, et al:
HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell
function, embryonic development, and tumor growth. Genes Dev.
20:557–570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dallas NA, Xia L, Fan F, et al:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang XQ, Feng YG and Wu MY: Effect of
5-Fu on the ratio of SP cells and expression of HIF-2α and ABCG2 in
human gastric cancer cell line SGC7901 under hypoxia. World Chinese
Journal of Digestology. 20:1813–1818. 2012.(In Chinese).
|
|
23
|
Steinbach G, Lynch PM, Phillips RK, et al:
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial
adenomatous polyposis. N Engl J Med. 342:1946–1952. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuo CH, Hu HM, Tsai PY, Wu IC, Yang SF,
Chang LL, Wang JY, Jan CM, Wang WM and Wu DC: Short-term celecoxib
intervention is a safe and effective chemopreventive for gastric
carcinogenesis based on a Mongolian gerbil model. World J
Gastroenterol. 15:4907–4914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rocha FT, Lourenço LG, Jucá MJ, Costa V
and Leal AT: Chemoprevention by celecoxib in reflux-induced gastric
adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
Acta Cir Bras. 24:189–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dandekar DS, Lopez M, Carey RI and
Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments
chemotherapeutic drug-induced apoptosis by enhancing activation of
caspase-3 and-9 in prostate cancer cells. Int J Cancer.
115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding H, Han C, Zhu J, Chen CS and
D’Ambrosio SM: Celecoxib derivatives induce apoptosis via the
disruption of mitochondrial membrane potential and activation of
caspase 9. Int J Cancer. 113:803–810. 2005. View Article : Google Scholar
|
|
28
|
Li Q, Peng J and Zhan GY: Effect of a
selective COX-2 inhibitor on cell proliferation and apoptosis in
human gastric cancer cell line BGC-823. Zhong Nan Da Xue Xue Bao Yi
Xue Ban. 33:1123–1128. 2008.(In Chinese).
|
|
29
|
Kim N, Kim CH, Ahn DW, et al: Anti-gastric
cancer effects of celecoxib, a selective COX-2 inhibitor, through
inhibition of Akt signaling. J Gastroenterol Hepatol. 24:480–487.
2009. View Article : Google Scholar
|
|
30
|
Wang Z, Chen H and Xia GH: Study on
celecoxib inducing gastric cancer cell apoptosis and its mechanism.
Journal of Modern Oncology. 17:416–420. 2009.(In Chinese).
|
|
31
|
Swamy MV, Herzog CR and Rao CV: Inhibition
of COX-2 in colon cancer cell lines by celecoxib increases the
nuclear localization of active p53. Cancer Res. 63:5239–5242.
2003.PubMed/NCBI
|
|
32
|
Erkinheimo TL, Lassus H, et al: Elevated
cyclooxygenase-2 expression is associated with altered expression
of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in
serous ovarian carcinoma. Clin Cancer Res. 10:538–545. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krysan K, Merchant FH, et al:
COX-2-dependent stabilization of survivin in non-small cell lung
cancer. FASEB J. 18:206–208. 2004.
|
